Last fall, Myovant reported phase 3 data that set its prostate cancer med up for an FDA filing, but it kept most details close to the vest. Now, it’s unveiling more as it awaits the agency’s decision.
The new data, to be presented at the virtual annual meeting of the American Society of Clinical Oncology, show just how quickly the drug, relugolix, can lower testosterone, which drives the growth of prostate cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,